Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy

Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior multi-agent chemotherapy regiments. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Montana, Wilbur, Buck, Dennis Andrew, Smith, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685419/
https://www.ncbi.nlm.nih.gov/pubmed/29158727
http://dx.doi.org/10.1159/000479224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685419/
https://www.ncbi.nlm.nih.gov/pubmed/29158727
http://dx.doi.org/10.1159/000479224

Ejemplares similares